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In diabetic patients, wound healing is impaired. We
studied the pathogenesis behind this clinical observation
by characterizing the pattern of deposition of extracellular
matrix (ECM) molecules and the cellular infiltrate in
chronic (>8 wk) diabetic wounds, compared with chronic
venous ulcers and an acute wound healing model. Punch
biopsies were obtained from the chronic ulcer margins
and control samples were collected from upper leg skin
5, 19, 28 d and 12 and 18 mo postwounding (p.w.). T
cells, B cells, plasma cells, granulocytes and macrophages,
and the ECM molecules fibronectin (FN), chondroitin
sulfate (CS), and tenascin (TN) were visualized using
immunohistochemical techniques. Expression of FN, CS,
and TN was detected in dermal tissue early in normal
wound healing (5–19 d p.w.). Abundant staining was seen
3 mo p.w., returning to prewounding levels after 12–18
mo p.w. In the dermis of chronic diabetic and venous
Clinical and experimental evidence shows that diabeticpatients as a group experience impaired wound healing(Goodson and Hunt, 1979; Spanheimer, 1991, 1992;Bennet and Schultz, 1993; Knighton and Fiegel, 1993).The mechanisms that contribute to poor wound healing
are not fully understood. Wound healing normally proceeds through
general stages such as hemostasis, inflammation, proliferation, epithelial-
ization and tissue remodelling. Many chronic wounds fail to complete
all these stages in healing. Diabetic ulcers are usually localized on
pressure points, such as the metatarso-phalangeal joints, ankles, or heel
region. The underlying pathology consists of neuropathy, ischemia
(both macro- and microcirculatory) and infection (Levin, 1993).
Infection plays an important role in the chronicity of these ulcers,
partially due to the adverse effect of diabetes on leukocyte chemotaxis
(Pereira et al, 1987; Thomas et al, 1991). Venous ulceration is
characterized by a specific pathophysiology consisting of venous stasis
and microcapillary pathology (Leu et al, 1980; Browse and Burnand,
1982; Fagrell, 1982; Coleridge Smith et al, 1988; Thomas et al, 1988;
Herrick et al, 1992). Due to the prolonged hydrostatic pressure, the
capillaries, which are originally not designed for high pressures, become
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ulcers with a duration of 12 mo or more, a prolonged
presence of these ECM molecules was noted. Compared
with normal wound healing: (i) the CD4/CD8 ratio in
chronic wounds was significantly lower (p < 0.0027) due
to a relatively lower number of CD4F T cells; (ii) a
significantly higher number of macrophages was present
in the edge of both type of chronic ulcers (p < 0.001
versus day 29 p.w.); and (iii) more B cells and plasma cells
were detected in both type of chronic wounds compared
with any day in the acute wound healing model (p < 0.04
for CD20F and p < 0.01 for CD79aF cells). These data
indicate that important differences exist in the cellular
infiltrate and ECM expression patterns of acute, healing
versus chronic wounds, which may be related to the
nonhealing status of chronic wounds. Key words: diabetes
mellitus/extracellular matrix molecules/immunophenotyping/
wound healing. J Invest Dermatol 111:850–857, 1998
dilated, twisted, and elongated and they start to leak plasma, proteins
(including fibrin), and erythrocytes in the surrounding tissue. Some
capillaries become occluded, while the blood flow in the remaining
dysfunctional capillaries is hampered. Generally, after a period of strict
bedrest, these capillary changes are reversed, and the ulcers show a
healing tendency, similar to acute wounds.
Based on the clinical observation that epithelialization can proceed
normally in these patients as soon as the quality of the wound bed has
improved, we hypothesize that the disturbances are located in the two
preceding phases, in the proliferation phase or the inflammation/
debridement phase.
The predominant cell types in early wound healing, especially in
the inflammation and debridement phase, are lymphocytes, granulocytes
and macrophages. The major function of granulocytes in wounds is to
eliminate contaminating bacteria. It has been known for long that
lymphocytes are present in healing wounds (Ross and Bendit, 1969)
but their function remains a topic of interest (Martin and Muir, 1990;
Barbul, 1992). Macrophages play a crucial regulatory role in the
transition between wound inflammation and the next phase of wound
repair, granulation tissue formation (Clark, 1985; Reed and Clark,
1985). This phase is characterized by proliferation of endothelial cells
and fibroblasts and the deposition of extracellular matrix (ECM)
molecules. During the repair process the ECM is sequentially remod-
elled and rebuilt by the action of different cell types and their products.
Fibronectin (FN) promotes adhesion of cells to the fibrin matrix,
acting as a scaffold for new matrix deposition, and also has chemotactic
capacities that regulate cell movement (Clark et al, 1982; Knox et al,
1986; Clark, 1988; Kim et al, 1992). Its expression is highly upregulated
in the dermis after wounding. Chondroitin sulfate (CS) is a disaccharide
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forming glycosaminoglycan (GAG) chains of different length. They are
covalently attached to core proteins forming chondroitin sulfate proteo-
glycans (CSPG) (Ruoslahti, 1989; Hardingham and Fosang, 1992). In
normal skin CSPG are mainly found in the basement membrane
(McCarthy et al, 1989; Daugaard et al, 1991) but in healing wounds they
are upregulated throughout the granulation tissue (Yeo et al, 1991) during
the second week of wound repair, when they provide a temporary matrix
with high hydrative capacity. Tenascin (TN) is an ECM glycoprotein
which occurs in the basement membrane and in granulation tissue. It is
known to have an influence on cell shape, and in vitro studies showed
that TN is important for maintaining tissue homeostasis by interfering
with cell migration and proliferation and by inhibiting cell adhesion to
FN (Kanno and Fukuda, 1994).
Very little is known about the expression of these above mentioned
ECM molecules and the composition of the cellular infiltrate in chronic
diabetic wounds.
The objective of this study was to investigate the expression of different
ECM molecules and to characterize the infiltrate composition in chronic
diabetic wounds versus chronic venous ulcers and an acute wound healing
model, in order to come to a better understanding of the process of
delayed wound healing in diabetes mellitus.
MATERIALS AND METHODS
Clinical profile This study was approved by the medical ethical committee
of the Academic Medical Center, Amsterdam, The Netherlands. Patients
were fully informed about the purpose and consequences of this study, and
subsequently gave their informed consent. Thirteen patients with diabetic ulcers
(noninsulin-dependent diabetes mellitus) with a mean age of 69.2 y admitted
to the clinic or visiting the outpatient department of our hospital were included
in this study. As a reference we compared the results to those of 12 patients
with a venous leg ulcer, with a mean age of 76 y, and an acute wound healing
model. A chronic ulcer was defined as existing for 8 wk or longer. Punch
biopsies of 4 mm were taken from the margin of chronic diabetic and venous
ulcers with a median ulcer duration, respectively, 11 (range 2–60) and 6 mo
(range 2.5–60). The biopsies were taken in such a manner that the epithelial
margin was included in the central part of the biopsy. The epithelial margin
can be considered as a reference point because normally the epithelium will
grow from here into the wound bed, only if the tissue underneath it has
reached a certain level of quality. When biopsies are taken at random from the
wound bed large differences can be encountered in the composition of the tissue.
The acute wound healing model was studied in three groups of patients. In
healthy agematched volunteers, acute wounds were made on the upper leg and
wound healing was studied at day 5, 19, and 28 postwounding (p.w.) in four
patients (mean age of patients 78.8, SD 13.3). During the study period the
wound area was covered with Opsite (Smith and Nephew, York, U.K.) to
establish a moist wound environment. The donor site (upper leg) for grafting
of chronic ulcers was rebiopsied 12 and 18 mo p.w. in one patient (age 64).
Wound healing 3 and 12 mo after breast reduction was studied in seven patients
(mean age 24.4, SD 4.4). All punch biopsies were taken under local anesthesia.
The biopsies were either fixed in 4% formalin phosphate-buffered saline (PBS)
solution, processed by routine histologic procedures and embedded in paraffin,
or snap-frozen and stored at –80°C until further processing.
Immunohistochemical staining
ECM molecules Polyclonal rabbit antibodies were used to detect FN (1:800,
Dako, Copenhagen, Denmark) and TN (1:400, Life Technologies, Breda, The
Netherlands) using a three-step labeling procedure with biotinylated polyclonal
swine-antibodies anti-rabbit IgG (1:400, Dako) as second antibody followed by
streptavidin biotinylated horseradish peroxidase (Hrp) complex (1:200, Dako).
For the detection of CS a mouse monoclonal antibody (1:300, Sigma, St. Louis,
MO) was used in a two step labeling procedure with as second step Hrp
conjugated goat antibodies antimouse IgM (1:200, Dako). Diaminobenzidine
(DAB) was obtained from Sigma.
Sections of 5–6 µm thickness were mounted on polylysine coated glass slides.
The sections were deparaffinized in xylol and hydrated through graded series
of ethanol. To remove endogenous peroxidase activity the slides were incubated
for 30 min in a 0.3% H2O2/methanol solution, washed with water and PBS.
Aspecific binding of antibodies was minimized by a 15 min preincubation with
10% normal goat serum (NGS) in PBS. The sections were incubated for 1 h
at room temperature with the first antibodies and washed three times with
PBS. Subsequently, the appropriate second antibody was applied, diluted in
PBS/10% NGS. If the second antibody was biotinylated a third incubation step
was performed with the streptavidin biotin complex conjugated with horse
radish peroxidase (streptABComplex/Hrp). After extensive washing to remove
nonbound antibodies, the color reaction was performed with DAB substrate.
Finally, the sections were counterstained with hematoxylin, mounted in glycergel
and examined. As recommended by the manufacturers, the fixed tissues used
for the FN staining were predigested with a 0.25% pepsin 10 mM HCl solution
pH 2.5 for 30 min at 37°C. A pepsin predigestion of sections for TN and CS
staining diminished the specific staining signal. The sections were examined
microscopically and photographs of representative staining were taken using an
Olympus SC35 camera (Tokyo, Japan) with 64T (EPY-135) Ektachrome film
(Kodak, The Netherlands). Sections of human normal skin served as positive
controls. As negative controls, adjacent sections of the wound biopsies were
stained with nonimmune IgG from the same species and in the same dilution
as the primary antibody. No staining was noted in the negative controls.
ECM quantitation FN, CS, and TN expression in the dermis of all chronic
and acute wounds was quantitated using a score system with a five point scale
(0, no expression; 1, weakly positive; 2, moderate; 3, strong; 4, very strong
expression). All specimens were evaluated blindly. In order to standardize the
results, the intensity of the ECM staining was correlated to the expression
found in the positive control sections. To check reproducibility, the slides were
examined by two independent observers, which yielded a correlation coefficient
of ù 0.83.
Lymphocytes, granulocytes, and macrophages Immunohistochemical single staining
was performed for the identification of T cells (CD3; pan T cells; 1:50; Becton
Dickinson), B cells (CD20 1:1000; Dako), plasma cells (CD79a 1:50; Dako),
granulocytes (CD15 1:50; Becton Dickinson) and monocytes, macrophages
(CD68 1:2000; Dako) based on a three-step indirect peroxidase technique.
Cryostat sections (6 µm) were allowed to dry overnight before fixing in acetone
for 10 min at room temperature. Endogenous peroxidase activity was blocked
with 0.1% sodium azide and 0.3% H2O2 in PBS for 10 min at room temperature.
For plasma cells, paraffin-embedded tissue sections were deparaffinized in xylol
and hydrated through a graded series of ethanol. To remove endogenous
peroxidase activity the slides were incubated for 30 min in a 0.3% H2O2/
methanol solution, washed with water and PBS. Antigen retrieval was achieved
by boiling the sections in 10 mM Citrate buffer; PH 6.0 (Dako). Aspecific
binding of antibodies was minimized by a 15-min preincubation with 10%
NGS in PBS. Briefly, the sections were incubated sequentially with primary
antibody for 60 min followed by an incubation with biotinylated secondary
monoclonal rabbit antimouse antibody (30 min). This was followed by an
incubation of 30 min with streptABComplex/Hrp (1:400, Dako). Before
counterstaining with hematoxylin, the horseradish peroxidase activity was
visualized with 3-amino-9-ethylcarbazole (AEC; Sigma) as chromogen for
cryostat sections and with DAB substrate for the paraffin sections.
For immunohistochemical double staining the following steps were per-
formed: (i) incubation of 60 min with a cocktail of rabbit antihuman CD3 plus
either mouse antihuman CD4 (1:20; Becton Dickinson) or mouse anti-human
CD8 (1:20, Becton Dickinson); (ii) an incubation of 30 min with a cocktail of
biotin-conjugated goat anti-mouse (1:200, Dako) plus alkaline phosphatase-
conjugated goat anti-rabbit (1:10, Dako) and an incubation of 30 min with
streptABComplex/Hrp (1:400, Dako). Alkaline phosphatase was detected as
blue color, using naphthol-AS-MX-phosphate as a substrate and fast blue BB
(Sigma) as azo dye. Peroxidase activity was detected as an orange red color,
using the chromogen AEC. Double staining cells were detected by their purple
color. The staining reaction was visually controlled and stopped by washing.
Sections were finally fixed in formaldehyde (4%) and mounted with glycerin-
gelatin without counterstaining. Sections of human tonsils served as positive
controls. The negative controls were stained in the same manner as all specimen
without incubation with the primary antibodies.
Cell enumeration The number of single or double stained cells of three different
serial sections of each wound were counted (blinded) up to a depth of 1 mm.
These values of each biopsy specimen were adjusted to 10 mm width. The
mean value of each biopsy was used for further analysis.
Statistical evaluation The unpaired Student’s t test was used for statistical
evaluation of differences in the composition of the cellular infiltrate between
each group. To detect the significance of differences in the CD4/CD8 ratio’s
and the number of B cells and plasma cells between acute and chronic wounds,
the Mann–Whitney U test was used. p values , 0.05 (two-tailed) were
considered significant.
RESULTS
ECM characterization
Fibronectin In normal skin FN could only be detected in bloodvessels
(Fig 1A). In sections of biopsies taken 19 d p.w. FN (Fig 1B) was
clearly present in the dermis. In time, FN staining increased markedly
until 3 mo p.w. (Fig 1C) to gradually decline towards 12–18 mo p.w.
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Figure 1. Prolonged expression of FN in
chronic diabetic and venous ulcers com-
pared to the acute wound healing model.
Sections of normal skin and acute wounds (day
19, 3 and 12 mo p.w.) as well as from the edge
of diabetic and venous ulcers were embedded
in paraffin and cut in 5–6 µm sections. FN was
detected as described in Materials and Methods.
In normal skin FN could only be detected in
blood vessels (a). Nineteen days p.w. expression
of FN was seen in the re-epithelialized ulcer
area and at the edge (b) to reach an intense
expression at 3 mo p.w. (c) and return to
prewounding levels 12 mo p.w. (d). In chronic
diabetic ulcers an intense staining for FN was
seen in the whole dermis of the ulcer area (e)
as well as in venous ulcers with a duration of
12 mo or more (not shown). Scale bars: (a, b)
70 µm; (c) 200 µm; (d) 300 µm; (e) 100 µm.
(Fig 1D). In chronic diabetic ulcers with a ulcer duration of more
than 12–18 mo, and in two venous ulcers, expression of FN was still
noted in the whole dermis of the ulcer area (Fig 1E).
Chondroitin sulfate CS labeling in normal skin was found in the
basement membrane (BM) and in the periphery of vascular structures
(Fig 2A). CS was detected after 19 d p.w. in the dermal tissue of acute
wounds (Fig 2B) and its expression became more intense up to 3 mo
p.w. (Fig 2C). At 12–18 mo p.w. CS staining in the dermis of all
acute wounds was back to prewounding levels (Fig 2D). All 25 chronic
wounds showed high CS expression in the dermis and basement
membrane (Fig 2E, F).
Tenascin In normal skin, TN staining was seen as a patch wise
distribution in the BM zone (Fig 3A). At 19 d p.w. TN started to be
expressed in the wound edge with the BM zone of the healthy skin
being positive (Fig 3B). At 3 mo p.w. strong expression of TN was
seen in the dermis (Fig 3C) which returned to prewounding levels at
12 mo (Fig 3D). The chronic wounds showed a light, moderate or
strong expression of TN in the dermis with great variability among
the ulcers. For diabetic ulcers two showed no (Fig 3E) and two
showed weak expression, four moderate, three strong and one very
strong TN expression (Fig 3F) in the dermis. Among venous ulcers
three showed no expression, two light, two moderate, and two strong
expression.
Figure 4(A) shows the quantitated FN expression in all individual
chronic ulcers as well as the acute wound healing model. In general
there was still high FN expression in the chronic diabetic and venous
wounds with a duration of more than 12 mo, when in normal wound
healing the level should be reduced again. In Fig 4(B, C), all chronic
ulcers and their dermal CS and TN expression are visualized versus the
acute wound healing model. There was a trend of prolonged CS and
TN expression in the dermis of venous and diabetic wounds with a
duration of more than 12 mo. Table I shows the original data for
ECM quantitation by two independent observers which yielded a
correlation coefficient of 0.88 for FN, 0.84 for CS, and 0.92 for TN.
Lymphocytes, granulocytes, and macrophages A common
observation in chronic wounds was a hyperkeratotic epidermis at the
wound edge with necrotic wound tissue heavily infiltrated with
inflammatory cells.
Figure 5 shows the kinetics of T and B cells, plasmacells, macro-
phages and granulocytes in acute and chronic wounds represented by
CD3 (Pan T cells), CD4 (helper-inducer T cells) CD8 (suppressor-
cytotoxic T cells), CD15 (granulocytes), CD20 (B cells), CD79a
(plasma cells) and CD68 (monocytes, macrophages) positive cells. In
the early stage of wound healing, there is an influx of T cells which
were predominantly of the CD31 CD41 type (Fig 5A, B). In chronic
wounds T cells were present although in a lower number than in the
acute wound healing model at any day (p , 0.0048 for venous ulcers
and p , 0.02 diabetic ulcers). This was mainly caused by a significantly
lower number of CD3 CD4 positive T cells in chronic wounds
(p , 0.0028 venous, p , 0.0029 diabetic ulcers) whereas the number
of CD81 T cells did not change dramatically (Fig 5C). CD4/CD8
ratio’s in acute wounds varied between 4.9 and 9.7 (Table II). In
chronic wounds the CD4/CD8 ratio was significantly depressed,
p , 0.0027, compared to any day in the acute wound healing model.
Granulocytes increased rapidly in number during the early phase after
wounding and decreased again after 5 d p.w.; they remained present
in chronic wounds (Fig 5D). B cells were detected at all time points
in acute wounds with a peak at day 19. B cells were present in
significantly higher numbers in both chronic wounds. In venous ulcers
a mean B cell number of 750 was found whereas at day 5, 19 and 28
p.w. there was a maximum of 200 B cells (p , 0.04). This was also
true for the diabetic ulcers (p , 0.006) (Fig 5E). Plasma cells were
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Figure 2. Prolonged expression of CS in
chronic diabetic and venous ulcers com-
pared to the acute wound healing model.
Sections of normal skin and acute wounds (day
19 and 3 and 12 mo p.w.) as well as from the
edge of diabetic and venous ulcers were fixed
and stained for CS. CS labeling in normal skin
was found in the basement membrane zone
and in the periphery of vascular structures (a).
Nineteen days p.w. CS was detected in the
dermal tissue of acute wounds (b) as well as at
3 mo p.w. (c). At 12 mo p.w. CS staining in
acute wounds was back to prewounding levels
(d). Both diabetic ulcers (e) and venous ulcers
(f) showed abundant expression of CS in the
dermis of the ulcer bed and edge. Scale bars: (a)
70 µm; (b) 260 µm; (c) 200 µm; (d) 300 µm;
(e) 160 µm; (f) 200 µm.
detected in significantly higher numbers (p , 0.0121) in both types
of chronic wounds compared to any day in the acute wound healing
(Fig 5F). Macrophages appeared together with T lymphocytes in the
initial phase of wounding in high numbers and in time their number
decreased. The number of macrophages in both chronic wounds was
significantly higher (diabetic ulcers, p , 0.0011 and venous ulcers,
p , 0.00001) compared to the last time point (day 28 p.w.) of the
acute wound healing model (Fig 5G).
DISCUSSION
The purpose of this study in a broader perspective was to find an
explanation on the cellular or molecular level for the clinical observation
that wound healing is delayed in diabetes mellitus.
In normal wound healing, the consecutive phases such as hemostasis,
inflammation and debridement, proliferation and remodelling, can be
identified by characteristic patterns of cellular infiltrate and ECM
deposition. Most chronic diabetic and venous ulcers fail to complete
all these stages of normal wound healing. We hypothesized that
the disturbances are located in the proliferation phase and/or the
inflammation and debridement phase. Once these phases have been
completed successfully, uncomplicated epithelialization will usually
follow.
We observed a prolonged expression of FN, CS, and TN in patient
material from 13 chronic diabetic ulcers and 12 venous ulcers, with a
duration of more than 12 mo. Although a semiquantitative evaluation
method was used to detect these ECM molecules, the statement that
this is an abnormal finding is valid because normally these matrix
molecules should only be present early in wound healing.
CS expression, investigated using a monoclonal antibody that can
detect all CSPG because it recognizes the GAG chains attached to the
core protein, e.g., decorin, CS-basement membrane proteoglycan, and
versican, was present far beyond the normal time frame of expression
seen in normal wound healing. CSPG expression has been shown to
be indicative for different stages of ECM regeneration and remodelling
in a porcine wound model (Lamme et al, 1996).
Abnormal patterns of FN and TN expression have also been observed
by other groups. Latijnhouwers et al (1996) reported a variable, but
mostly upregulated TN expression in the papillary dermis adjacent to
the ulcer base of chronic venous ulcers. Ferguson et al (1996) demon-
strated the presence of small abnormal blood vessels at the wound edge
and base of diabetic ulcers, sometimes cuffed with collagen, laminin,
FN and fibrin. Herrick et al (1992) showed a upregulated TN and FN
expression in the ulcer margin and a weak positive ulcer base for TN
and the absence of FN in the ulcer base of venous ulcers. The
distribution of TN during wound healing has been studied in animal
models and to a lesser extent in human skin. TN has been reported
to be upregulated primarily in the first two weeks p.w., first in the
dermal areas adjacent to the wound bed and later in the wound bed
(Latijnhouwers et al, 1996), to gradually disappear after 1.5 mo (Betz
et al, 1993). A strong but transient increase in TN expression (maximum
at 4 d p.w., towards baseline at day 11) has been described in rats
(Luomanen and Virtanen, 1993).
Studies on the composition of the cellular infiltrate in chronic
wounds are scarce. An explanation might be that patient material is
difficult to obtain for practical and ethical reasons.
Several hypotheses have been proposed to explain delayed wound
healing in diabetes, such as glycosylation of important structural proteins
and growth factors, a possible deficit in specific growth factor production
or release into the wound (Knighton and Fiegel, 1993) and impairment
of leukocyte (Thomas et al, 1991) or macrophage function (Moore
et al, 1997). Some of these mechanisms may be related.
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Figure 3. Prolonged expression of TN in
chronic diabetic and venous ulcers com-
pared to the acute wound healing model.
Sections of normal skin and acute wounds (day
19, 3, and 12 mo p.w.) as well as from the edge
of diabetic and venous ulcers were fixed and
stained as described in Materials and Methods. In
normal skin TN expression was seen as a patch
wise distribution in the BM zone (a). At 19 d
p.w. TN started to be expressed in the ulcer
edge of acute wounds with a positive BM zone
of the healthy tissue (b). At 3 mo p.w. the most
prominent expression of TN was seen in the
dermis (c) and 12 mo p.w. TN expression was
back to prewounding levels (d). Both chronic
diabetic and venous ulcers showed variability
in TN expression in the dermis varying from
absence of expression (diabetic ulcer f) to, in
most cases, prolonged expression (diabetic ulcer
e). Scale bars: (a) 70 µm; (b–d) 200 µm; (e, f)
120 µm.
Glycosylation In diabetes it has been postulated that excessive
formation of advanced glycosylated end products in the presence of
continuously elevated blood glucose may overwhelm the body’s ability
to remove them, resulting in a net excess of advanced glycosylated
end products on most of the structural proteins, leading to an altered
recognition by their cellular receptors (Makita et al, 1991). The absence
of a negative feedback mechanism may lead to overproduction of
ECM. It has been shown in vitro that exposure of mesangial cells to
advanced glycosylated end products was followed by an increase
in ECM mRNA and FN production, which is the hallmark of
glomerulosclerosis, and a decrease in cellular proliferation (Skolnik
et al, 1991; Doi et al, 1992). The mechanisms that lead to nephropathy
in diabetes may be similar to those leading to delayed wound healing.
Growth factors/cytokines The observed expression of FN, CS
and TN in the edge of chronic wounds shows that there is a potential
to heal since it is a natural pattern of acute wounds to express these
molecules at the onset of the healing process. Normally, fibroblasts
eventually cease to produce these provisional ECM molecules, possibly
by inhibitory growth factors that are secreted in the next phase of
wound healing, granulation tissue formation. An imbalance of cytokines
in the chronic wound bed or edge and the presence of inflammatory
cells could be responsible as well for the continued production of
ECM molecules. ECM degradation is also taking place: FN degradation
products have been observed in chronic skin ulcers (Wysocki and
Grinell, 1990; Grinnell et al, 1992; Palohlahti et al, 1993) as well as
elevated levels of several proteinases-gelatinases in wound fluid (Stacey
et al, 1993; Wysocki et al, 1993). It seems that in these chronic
nonhealing ulcers both excess deposition of ECM molecules and
increased proteolytic activity against ECM molecules are present. TGF-
β and activated CD41 T lymphocytes have been shown to trigger
synovial fibroblasts and epitenon cells to increase their production of
FN (Wojciak and Crossan, 1993, 1994).
Impairment of leukocyte or macrophage function The pre-
viously mentioned leukocyte impairment may be responsible for delays
in the inflammation phase in diabetic patients. Compared to normal
wound healing, in chronic venous and diabetic ulcers the CD4/CD8
ratio was significantly lower due to a relatively lower number of
CD41 T cells compared to the acute wounds. Moore et al (1997)
found a comparable CD4/CD8 ratio for chronic venous ulcers (1.5).
Apparently, diabetic ulcers have a similar depressed CD4/CD8 ratio
(1.25). It has been suggested in the literature that the continued
presence of lymphocytes, and especially the predominance of CD81 T
cells may impede certain stages of the healing process (Breslin et al,
1988; Barbul and Regan, 1990). This theory is supported by the
accelerated healing process following the depletion of CD81 cells in
acute wounds in mice (Barbul et al, 1989).
In the acute wound healing model B cells were detected with a
peak at day 19. A significantly higher number of B cells was present
in chronic wounds. According to the literature B cells are not present
in normal skin. Rosner et al (1995) found a relatively low number of
B cells in the edge of venous ulcers comprising less than 3% of the
dermal infiltrate. We biopsied chronic ulcera in a nonhealing stage,
and a continuous exposition to bacteria might be responsible for the
increased number of B cells. The observation that significantly more
plasma cells were present in the chronic ulcers also supports this
hypothesis, because a plasmacellular infiltrate is often associated with
the presence of microorganisms.
Macrophages appear together with T cells in the initial phase of
wound healing. They play a key role in the transition from the
inflammatory phase to the proliferating phase (Falanga et al, 1990;
Hammer, 1993). Although macrophages dominate the ulcer edge of
both diabetic and venous ulcers, they seem to be unable to direct the
repair process towards the proliferative phase. Our finding is in
concordance with the results of one other study on phenotyping of
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Figure 4. Prolonged expression of FN, CS, and TN in chronic ulcers
versus acute wounds. FN (a), CS (b), and TN (c) expression in the dermis of
sections of acute and chronic wounds was scored in one session on a five point
scale by two independent observers (c.c 0.83). Their expression in acute wounds
(5 and 19 d p.w., 4 wk, 3 mo, 12 mo, and 18 mo p.w.) was visualized as a
reference line for uncompromised wound healing. The majority of the chronic
diabetic and venous ulcers showed strong and or prolonged expression of these
ECM molecules in the dermis as indicated outside the reference line. Error bars:
SD (n 5 4).
immunocompetent cells in venous leg ulcers (Rosner et al, 1995).
These authors also showed that the venous ulcer edge was mainly
populated by macrophages. Recently, Moore and coworkers reported
that monocytes appeared to be active perivascular in venous ulcers but
while penetrating the wound bed as macrophages they lost their
activation markers (Moore et al, 1997).
In summary, there appears to be a disturbance in the phase of
inflammation and debridement and in the proliferation phase. Distinct
patterns of ECM deposition and a different composition of the cellular
infiltrate were observed in chronic diabetic and venous ulcers. Although
both chronic wound types have a different pathophysiology, the
Table I. ECM quantitation by two independent observersa
FN CS TN
Diabetic ulcers
#1 3/3 2/2 1/1
#2 2/3 3/3 3/3
#3 4/4 3/4 4/4
#4 3/3 3/4 3/3
#5 2/3 2/3 2/2
#6 3/3 4/4 0/0
#7 3/3 4/4 0/0
#8 2/2 2/2 2/2
#9 4/4 1/1 1/1
#10 3/3 2/3 2/2
#11 3/3 2/2 3/3
#12 3/4 3/4 2/2
Venous ulcers
#1 2/2 4/4 0/0
#2 3/3 3/4 0/0
#3 2/2 3/3 0/0
#4 2/3 3/3 1/1
#5 3/3 4/4 3/3
#6 3/3 3/2 2/2
#7 3/3 3/3 3/3
#8 3/2 2/2 2/2
#9 2/2 2/2 1/2
Acute wound model
day 5
#1 1/1 2/2 1/1
#2 2/2 2/2 0/1
#3 1/2 3/3 1/2
#4 –/– 1/1 0/0
day 19
#1 4/4 2/3 1/2
#2 4/4 3/3 1/1
#3 3/3 3/3 1/1
#4 2/2 2/2 2/2
4 wk
#1 3/3 4/3 2/2
#2 3/2 4/2 2/2
#3 3/3 3/3 2/3
#4 3/3 4/3 2/3
3 mo
#1 4/4 4/3 3/3
#2 4/3 3/2 3/2
#3 4/3 3/2 4/4
12 mo
#1 2/2 1/0 1/0
#2 2/2 1/0 1/0
#3 3/3 0/0 0/0
#4 1/1 0/0 0/1
18 mo 0/0 0/0 –/–
aCorrelation coefficient: FN 0.88, CS 0.84, TN 0.92.
observed abnormalities in ECM quantitation and infiltrate immuno-
phenotyping are very comparable. While in acute wounds the inflam-
matory phase is of short duration and directed at removal of bacteria
and dead tissue, with polymorphonuclear leukocytes and macrophages
as the predominant cell types, in chronic wounds there is a prolonged
and increased presence of a T cell infiltrate, with an abnormal CD4-
CD8 balance, and an increased number of macrophages, without any
evidence of increased autodigestion and phagocytosis. These chronic
venous and diabetic ulcers seem to be frozen in a chronic low-grade
inflammatory state, in the sense that completion of the digestive tasks
and transition into the next phase, proliferation of fibroblasts and
endothelial cells, is not taking place.
Similar remarks can be made regarding the proliferation phase: large
amounts of ECM molecules are being produced but the composition
resembles the pattern seen in late phases (2–3 mo) of normal wound
healing. The molecules are not removed or remodelled within a normal
timeframe as in acute wounds. In fact, the composition of the ECM
and cellular infiltrate share properties of both the inflammatory phase
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Figure 5. Reduced numbers of CD41 T cells and high numbers of B
cells, plasma cells and macrophages in chronic diabetic and venous
ulcers compared with the acute wound healing model. Kinetics of T cells
represented by CD31, CD41 and CD81 cells (a–c), granulocytes (CD151, d),
B cells (CD201, e), plasma cells (CD79a1, f) and macrophages (CD681, g) in
the acute wound healing model and in chronic diabetic and venous ulcers.
Skin biopsies were taken from the upper leg at day 5, 19, and 28 p.w. as well
as from the edge of diabetic and venous ulcers and snap-frozen.
Immunohistochemical single and double staining techniques and cell counting
were performed as described in Material and Methods. Venu, venous ulcers;
Diabu, diabetic ulcers. Error bars: SD (n 5 4–7), triple countings per patient.
Day 5, 19, and 28 p.w. Error bars: SD (n 5 1–4), triple countings for each time
point per patient. (a, b, e, f) *p , 0.05 for number of positive cells per 10 mm2
in diabetic and venous ulcers compared to any day in the acute wound healing
model. (g) *p , 0.05 for number of positive cells per 10 mm2 in diabetic and
venous ulcers compared with day 28 acute wounds.
Table II. Depressed CD4/CD8 ratios in chronic versus normal
wound healing
Wound type CD4/CD8 ratio
Venous ulcers 0.59 (p , 0.0015)a
Diabetic ulcers 1.25 (p , 0.0027)
Day 5 acute wound 8.6
Day 19 acute wound 9.7
Day 28 acute wound 4.9
ap values are in parentheses and compare venous and diabetic ulcers to any day in the
acute wound healing model.
and proliferation phase, and it is likely that the classification criteria
that we use to define healing stages in acute wounds are not applicable
at all in chronic leg ulcers.
We gratefully acknowledge Mr. F.B. Niessen for supplying skin biopsies from healing
wounds.
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